Leukemia Research
Volume 33, Issue 12 , Pages 1623-1626 , December 2009

Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia

  • Lauren Véronèse

      Affiliations

    • Univ Clermont 1, Fac Médecine, Histologie Embryologie Cytogénétique, Clermont-Ferrand F-63001, France
    • CHU Clermont-Ferrand, Cytogénétique Médicale, Clermont-Ferrand F-63003, France
    • Univ Clermont 1, Fac Médecine, EA 3846, Clermont-Ferrand F-63011, France
    • Service d’Hématologie Clinique Adulte, CHU, Clermont-Ferrand F-63003, France
    • ,
  • Olivier Tournilhac

      Affiliations

    • Univ Clermont 1, Fac Médecine, EA 3846, Clermont-Ferrand F-63011, France
    • Service d’Hématologie Clinique Adulte, CHU, Clermont-Ferrand F-63003, France
    • ,
  • Pierre Verrelle

      Affiliations

    • Univ Clermont 1, Fac Médecine, EA 3846, Clermont-Ferrand F-63011, France
    • Département de Radiothérapie, Centre Jean Perrin, Clermont-Ferrand F-63011, France
    • ,
  • Frédéric Davi

      Affiliations

    • Service d’Hématologie Biologique & Université Pierre et Marie Curie, Hôpital Pitié-Salpêtrière, Paris F-75013, France
    • ,
  • Guillaume Dighiero

      Affiliations

    • Institut Pasteur de Montevideo, Montevideo 11400, Uruguay
    • ,
  • Emmanuel Chautard

      Affiliations

    • Univ Clermont 1, Fac Médecine, EA 3846, Clermont-Ferrand F-63011, France
    • ,
  • Richard Veyrat-Masson

      Affiliations

    • Univ Clermont 1, Fac Médecine, EA 3846, Clermont-Ferrand F-63011, France
    • Service d’Hématologie Biologique, CHU, Clermont-Ferrand F-63003, France
    • ,
  • Fabrice Kwiatkowski

      Affiliations

    • Service Statistiques et Communications Médicales, Centre Jean Perrin, Clermont-Ferrand F-63011, France
    • ,
  • Carole Goumy

      Affiliations

    • Univ Clermont 1, Fac Médecine, Histologie Embryologie Cytogénétique, Clermont-Ferrand F-63001, France
    • CHU Clermont-Ferrand, Cytogénétique Médicale, Clermont-Ferrand F-63003, France
    • ,
  • Laetitia Gouas

      Affiliations

    • Univ Clermont 1, Fac Médecine, Histologie Embryologie Cytogénétique, Clermont-Ferrand F-63001, France
    • CHU Clermont-Ferrand, Cytogénétique Médicale, Clermont-Ferrand F-63003, France
    • ,
  • Jacques-Olivier Bay

      Affiliations

    • Univ Clermont 1, Fac Médecine, EA 3846, Clermont-Ferrand F-63011, France
    • Service d’Hématologie Clinique Adulte, CHU, Clermont-Ferrand F-63003, France
    • ,
  • Philippe Vago

      Affiliations

    • Univ Clermont 1, Fac Médecine, Histologie Embryologie Cytogénétique, Clermont-Ferrand F-63001, France
    • CHU Clermont-Ferrand, Cytogénétique Médicale, Clermont-Ferrand F-63003, France
    • ,
  • Andrei Tchirkov

      Affiliations

    • Univ Clermont 1, Fac Médecine, Histologie Embryologie Cytogénétique, Clermont-Ferrand F-63001, France
    • CHU Clermont-Ferrand, Cytogénétique Médicale, Clermont-Ferrand F-63003, France
    • Univ Clermont 1, Fac Médecine, EA 3846, Clermont-Ferrand F-63011, France
    • Département de Radiothérapie, Centre Jean Perrin, Clermont-Ferrand F-63011, France
    • Corresponding Author InformationCorresponding author at: Service de Cytogénétique Médicale, CHU, UFR Médecine, Place Henri Dunant - BP 38, 63001 Clermont-Ferrand Cedex 1, France. Tel.: +33 4 73 17 81 10; fax: +33 4 73 26 91 82.

Received 14 January 2009 ,Revised 30 April 2009 ,Accepted 4 May 2009.

References 

  1. Véronèse L, Tournilhac O, Verrelle P, Davi F, Dighiero G, Chautard E, et al. Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia. Leukemia. 2008;22:1291–1293
  2. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008;112:3807–3817
  3. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007;13:2144–2150
  4. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004;104:2886–2892
  5. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phophorylation status and apoptosis is modulated by a green tea component, epigalloatechin-3-gallate (EGCG) in B-cell chronic lymphocytic leukaemia. Blood. 2004;104:788–794
  6. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukaemia (CLL) B cells interact with STAT1 and 3: implications for apoptosis resistance. Leukemia. 2005;19:513–523
  7. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, et al. Interleukin-6 upregulates myeloid cell leukaemia-1 expression through a STAT3 pathway in cholangiocarcinome cells. Hepatology. 2005;42:1329–1338
  8. Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, et al. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol. 2008;617:547–555
  9. Pepper C, Ward R, Lin TT, Brennan P, Starczynski J, Musson M, et al. Highly purified CD38+ and CD38− sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia. 2007;21:687–696
  10. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17:2474–2486
  11. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003;9:3369–3375
  12. Tchirkov A, Khalil T, Chautard E, Mokhtari K, Véronèse L, Irthum B, et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer. 2007;96:474–476
  13. Maloum K, Pritsch O, Magnac C, Vuillier F, Dighiero G, Troussard X, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood. 2000;96:377–379
  14. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003;101:1262–1269
  15. Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukaemia cells. Blood. 2000;96:3181–3187
  16. Bayrey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukaemia (CLL) cells. Leuk Res. 2004;28:243–248
  17. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111:846–855
  18. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol. 1999;19:6195–6206
  19. Biondi A, Rossi V, Barbui T, Bettoni S, Sironi M, Mantovani A, et al. Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukaemia. Blood. 1989;73:1279–1284
  20. Lavabre-Bertrand T, Exbrayat C, Liautard J, Gaillard JP, Baskevitch PP, Poujol N, et al. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br J Haematol. 1995;91:871–877
  21. Moreno A, Villar ML, Cámara C, Luque R, Cespón C, González-Porqué P, et al. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood. 2001;97:242–249
  22. Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lerner S, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256–263
  23. Lai R, O’Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, et al. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer. 2002;95:1071–1075

PII: S0145-2126(09)00252-5

doi: 10.1016/j.leukres.2009.05.003

Leukemia Research
Volume 33, Issue 12 , Pages 1623-1626 , December 2009

Article Tools

* Image Usage & Resolution